Dr Adam Clarke leads channel bio with almost 15 years of industry experience in the generation, optimisation and pre-clinical development of biologics. As a protein engineer, Adam has pioneered techniques in the discovery and engineering of monoclonal antibodies against challenging targets. Prior to joining channel bio, Adam was most recently Senior Director, Biologics Lead Antibody Discovery at Teva Pharmaceuticals. During his time at Teva, Adam led a team of scientists that consistently generated therapeutic antibodies that proceeded to first-in-human trials, several of which are currently in later stage clinical trials. Adam completed postgraduate training in experimental medicine, earning a PhD from the University of Sydney (Prof Tony Weiss lab). He is the holder of 15 patent families and 12 scientific publications.
Anne is the Vice President of Business Development at AbCellera and serves on the Board of Directors of LifeSciences BC and Aequus Pharmaceuticals. Previously, Anne was a Co-Founder and Senior Partner of Northview Lifesciences, an entity which invests in and provides strategic advisory services to a number of life sciences companies. Anne also served as the Chief Operating Officer for Aequus Pharmaceuticals, a publicly listed Canadian specialty pharmaceutical company where she was responsible for developing and executing on the corporate strategy, including building out the commercial pipeline through the execution of various types of partnerships with multi-national organizations. Anne’s earlier experience includes roles of increasing responsibility in business and corporate development, including at Cardiome Pharma Corp. and Bayer HealthCare, where she was responsible for strategic planning and value analysis of internal R&D as well as the commercial success and business development of a portfolio of products within several key therapeutic areas.
Anne holds a Bachelor of Science degree and Master of Health Administration degree from University of British Columbia and is a past winner of Business in Vancouver’s “Top 40 Under 40 Award”.
Neil Aubuchon is the Chief Commercial Officer at AbCellera. He has over 23 years of commercial experience at multinational bio-pharmaceutical companies. He has held a wide array of positions both within markets and at the global level, including leading a 1,000+ person organization.
Prior to joining AbCellera, Neil was the Global Marketing Lead for Amgen’s General Medicine early portfolio, which included responsibility for developing the integrated strategy for Amgen’s non-oncology therapeutic areas and leading commercial strategy for over 10 biologics, as well as several high profile corporate initiatives. Prior to Amgen, Neil was the Vice President of Global Marketing at Santen, a global ophthalmology-focused pharmaceutical company. Prior to Santen, Neil spent close to 17 years at Eli Lilly in various commercial roles of increasing responsibility. This included the Chief Marketing Officer in Australia, Chief Marketing Officer in Japan, Head of Strategy & Operations for Lilly Bio-Medicines Globally, and Vice President of Lilly Bio-Medicines in Japan.
Neil holds a BA in Political Science from the University of Western Ontario and an MBA from the University of Toronto.
Tiffany joined AbCellera in 2020 and leads strategic communications. She brings more than 17 years of experience translating science and technology into content that stimulates, educates, and catalyzes change. She co-founded Centrifuge Media Lab in 2010, where she led strategy and brand development for biotech, life science, and tech clients across the globe. Tiffany was previously the Global Communications Lead for Accenture at Best Buy and has held senior roles in the STEMCELL Technologies Group of Companies. She is currently on the Board of Directors for the Spring for Kids Foundation and is the past President of the Vancouver Asian Canadian Theatre. Tiffany completed her BSc in Integrated Science from the University of British Columbia.